3353.T
The company operates in the drug retailing sector, generating revenue primarily through the sale of pharmaceuticals and related health products.
Business. The company operates in the drug retailing sector, generating revenue primarily through the sale of pharmaceuticals and related health products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the drug retailing sector, generating revenue primarily through the sale of pharmaceuticals and related health products.
The company maintains a capital structure with a debt-to-equity ratio of 0.66, indicating a moderate reliance on debt financing. Its liquidity position is characterized by a current ratio of 1.65, suggesting the company has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.
In terms of profitability, the company's return on equity is 8.16%, which is a measure of how effectively the company generates profit from shareholders' equity. The return on assets of 3.4% indicates the efficiency of the company in generating profit from its total assets. These metrics should be compared against the industry's preferred metrics and cohort medians to assess the company's performance relative to its peers.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no significant geographic diversification mentioned in the available data. This concentration may expose the company to higher risks if the segment or region experiences downturns.
The company's growth trajectory is reflected in its recent financial performance, with a revenue of 54,982,518,000 JPY. The outlook for the current fiscal year and the next fiscal year is not explicitly provided, but the company's historical revenue and operating cash flow suggest a stable financial position.
The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests that the company may need to manage its liquidity carefully to avoid financial distress. The dilution potential is low, and no significant adjustments have been applied to the valuation metrics.
Recent events, such as filings and transcripts, are not detailed in the provided data. However, the company's financial statements and analyst estimates provide insights into its recent performance and expectations.
- The company has a moderate debt-to-equity ratio, indicating a balanced capital structure.
- The company's return on equity is relatively high, suggesting effective use of shareholders' equity.
- The company's liquidity position is moderate, with a current ratio of 1.65.
- The company's net cash position is negative after subtracting total debt, which may pose liquidity challenges.
- The company's revenue is concentrated in a single segment, which may increase its exposure to market risks.
- **margin_outlook_rationale**: The company's gross profit margin is expected to remain stable, driven by consistent pricing and cost management strategies.
- **rd_outlook_rationale**: Research and development expenditures are not a significant focus for the company, as it primarily operates in a retail sector with limited R&D requirements.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 3353.T Market data — financials · 2026-05-26
- Medical Ikkou Group Co Ltd Market data — analyst estimates · 2026-05-26